These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

398 related articles for article (PubMed ID: 24283718)

  • 1. The role of PD-1 and PD-L1 in T-cell immune suppression in patients with hematological malignancies.
    Shi L; Chen S; Yang L; Li Y
    J Hematol Oncol; 2013 Sep; 6(1):74. PubMed ID: 24283718
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PD-1 /PD-L1 checkpoint in hematological malignancies.
    Annibali O; Crescenzi A; Tomarchio V; Pagano A; Bianchi A; Grifoni A; Avvisati G
    Leuk Res; 2018 Apr; 67():45-55. PubMed ID: 29428449
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting regulatory T cells in anti-PD-1/PD-L1 cancer immunotherapy.
    Zhulai G; Oleinik E
    Scand J Immunol; 2022 Mar; 95(3):e13129. PubMed ID: 34936125
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biomarkers for checkpoint inhibition in hematologic malignancies.
    Atanackovic D; Luetkens T
    Semin Cancer Biol; 2018 Oct; 52(Pt 2):198-206. PubMed ID: 29775689
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PD-L1 engagement on T cells promotes self-tolerance and suppression of neighboring macrophages and effector T cells in cancer.
    Diskin B; Adam S; Cassini MF; Sanchez G; Liria M; Aykut B; Buttar C; Li E; Sundberg B; Salas RD; Chen R; Wang J; Kim M; Farooq MS; Nguy S; Fedele C; Tang KH; Chen T; Wang W; Hundeyin M; Rossi JAK; Kurz E; Haq MIU; Karlen J; Kruger E; Sekendiz Z; Wu D; Shadaloey SAA; Baptiste G; Werba G; Selvaraj S; Loomis C; Wong KK; Leinwand J; Miller G
    Nat Immunol; 2020 Apr; 21(4):442-454. PubMed ID: 32152508
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape.
    Jiang X; Wang J; Deng X; Xiong F; Ge J; Xiang B; Wu X; Ma J; Zhou M; Li X; Li Y; Li G; Xiong W; Guo C; Zeng Z
    Mol Cancer; 2019 Jan; 18(1):10. PubMed ID: 30646912
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blockage of immune checkpoint molecules increases T-cell priming potential of dendritic cell vaccine.
    Hassannia H; Ghasemi Chaleshtari M; Atyabi F; Nosouhian M; Masjedi A; Hojjat-Farsangi M; Namdar A; Azizi G; Mohammadi H; Ghalamfarsa G; Sabz G; Hasanzadeh S; Yousefi M; Jadidi-Niaragh F
    Immunology; 2020 Jan; 159(1):75-87. PubMed ID: 31587253
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Programmed death-1 checkpoint blockade in acute myeloid leukemia.
    Sehgal A; Whiteside TL; Boyiadzis M
    Expert Opin Biol Ther; 2015; 15(8):1191-203. PubMed ID: 26036819
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PD-1/PD-L1 Pathway in Breast Cancer.
    Schütz F; Stefanovic S; Mayer L; von Au A; Domschke C; Sohn C
    Oncol Res Treat; 2017; 40(5):294-297. PubMed ID: 28346916
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Programmed cell death protein 1 activation preferentially inhibits CD28.CAR-T cells.
    Zolov SN; Rietberg SP; Bonifant CL
    Cytotherapy; 2018 Oct; 20(10):1259-1266. PubMed ID: 30309710
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations.
    Jiang Y; Chen M; Nie H; Yuan Y
    Hum Vaccin Immunother; 2019; 15(5):1111-1122. PubMed ID: 30888929
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway.
    Ohaegbulam KC; Assal A; Lazar-Molnar E; Yao Y; Zang X
    Trends Mol Med; 2015 Jan; 21(1):24-33. PubMed ID: 25440090
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PD-1/PD-L1 Blockade Enhances T-cell Activity and Antitumor Efficacy of Imatinib in Gastrointestinal Stromal Tumors.
    Seifert AM; Zeng S; Zhang JQ; Kim TS; Cohen NA; Beckman MJ; Medina BD; Maltbaek JH; Loo JK; Crawley MH; Rossi F; Besmer P; Antonescu CR; DeMatteo RP
    Clin Cancer Res; 2017 Jan; 23(2):454-465. PubMed ID: 27470968
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biochemical signaling of PD-1 on T cells and its functional implications.
    Boussiotis VA; Chatterjee P; Li L
    Cancer J; 2014; 20(4):265-71. PubMed ID: 25098287
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune checkpoint blockade: Releasing the brake towards hematological malignancies.
    Xia Y; Medeiros LJ; Young KH
    Blood Rev; 2016 May; 30(3):189-200. PubMed ID: 26699946
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of chemotherapy on programmed cell death 1/programmed cell death 1 ligand axis: some chemotherapeutical drugs may finally work through immune response.
    Luo M; Fu L
    Oncotarget; 2016 May; 7(20):29794-803. PubMed ID: 26919108
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune suppression by neutrophils in HIV-1 infection: role of PD-L1/PD-1 pathway.
    Bowers NL; Helton ES; Huijbregts RP; Goepfert PA; Heath SL; Hel Z
    PLoS Pathog; 2014 Mar; 10(3):e1003993. PubMed ID: 24626392
    [TBL] [Abstract][Full Text] [Related]  

  • 18. What does PD-L1 positive or negative mean?
    Ribas A; Hu-Lieskovan S
    J Exp Med; 2016 Dec; 213(13):2835-2840. PubMed ID: 27903604
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Subverting the B7-H1/PD-1 pathway in advanced melanoma and kidney cancer.
    Harshman LC; Choueiri TK; Drake C; Stephen Hodi F
    Cancer J; 2014; 20(4):272-80. PubMed ID: 25098288
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An optimized protocol for the in vitro generation and functional analysis of human PD1/PD-L1 signal.
    Khedri M; Abnous K; Rafatpanah H; Ramezani M
    J Recept Signal Transduct Res; 2018 Feb; 38(1):31-36. PubMed ID: 29252078
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.